文献速递脊柱关节炎

银屑病关节炎疾病影响问卷(PsAID)在MDA中替代HAQ的新作用

A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire.
PubMed 文献 · Semin Arthritis Rheum · 2019-04-19

该研究在115例银屑病关节炎患者中验证PsAID问卷,基于cDAPSA生成四个PsAID切点用于MDA。PsAID与9种PROMs中度相关(ρ=0.51-0.78),四种PsAID-MDA版本对HAQ-MDA的敏感性均>85%,三种版本特异性>85%,提示PsAID可有效替代HAQ用于MDA。

要点

  • PsAID与临床PROMs中度相关,可作为PsA患者报告结局工具。
  • 基于cDAPSA生成四个PsAID切点用于MDA。
  • PsAID-MDA对HAQ-MDA敏感性和特异性均较高,可替代HAQ。

核心结论

  • PsAID-MDA与HAQ-MDA相比具有高敏感性和特异性,提示PsAID可有效替代HAQ用于MDA。

研究设计与样本

  • 从PsA门诊招募患者,按标准方案评估人口学、临床特征和实验室检查,计算描述性统计。
  • 共115例患者完成PsAID,其中男性70例、女性45例,平均PsA病程18.7(±11.6)年。

主要发现

  • PsAID-9和PsAID-12平均分分别为3.4(±2.4)和3.2(±2.3)。
  • PsAID与临床使用的9种PROMs中度相关(ρ=0.51-0.78)。
  • 基于cDAPSA生成四个PsAID切点用于MDA:缓解PsAID-9、缓解PsAID-12、低疾病活动度PsAID-9和低疾病活动度PsAID-12。
  • 四种PsAID-MDA版本对HAQ-MDA的敏感性均大于85%,其中三种版本特异性大于85%。

关键数值与推荐

  • PsAID-9平均分3.4(±2.4),PsAID-12平均分3.2(±2.3)。
  • PsAID与9种PROMs的相关系数ρ=0.51-0.78。
  • 四种PsAID-MDA版本对HAQ-MDA敏感性>85%,三种版本特异性>85%。

临床怎么用

  • 在PsA患者MDA评估中,可考虑用PsAID替代HAQ作为患者报告结局指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Minimal Disease Activity (MDA) uses the Health Assessment Questionnaire (HAQ) as one criterion. HAQ does not correlate well with disease activity with increased PsA disease duration, and its use in the MDA has been questioned. The Psoriatic Arthritis Impact of Disease (PsAID) was specifically developed for PsA Patients. We aimed to validate the PsAID within our patient cohort and determine if the PsAID can replace the HAQ in the MDA. METHODS: Patients were recruited from the PsA clinic and assessed according to a standard protocol including demographics, clinical features and laboratory tests. Descriptive statistics were calculated. PsAID cut-offs for use in the MDA were generated based on the Clinical Disease Activity for Psoriatic Arthritis (cDAPSA). RESULTS: 115 patients completed the PsAID. There were 70 males, 45 females, with a mean PsA duration of 18.7 (±11.6) years. Mean scores of PsAID-9 and PsAID-12 were 3.4 (±2.4) and 3.2 (±2.3), respectively. The PsAID correlated moderately well with 9 of the PROMs administered in the clinic (ρ = 0.51-0.78). Four PsAID cutoffs based on cDAPSA were generated for use in the MDA: remission (REM) PsAID-9, REM PsAID-12, low disease activity (LDA) PsAID-9, and LDA PsAID-12. All four versions of the PsAID MDAs had sensitivity greater than 85% with the HAQ-MDA, and three versions of the PsAID-MDA had specificity greater than 85% with the HAQ-MDA. CONCLUSIONS: The high sensitivity and specificity of the PsAID-MDA with the HAQ-MDA suggest that the PsAID is an effective replacement for the HAQ in the MDA.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Johnson K, Ye JY, Chandran V, et al. A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire. Semin Arthritis Rheum. 2019. PMID: 31101369. doi:10.1016/j.semarthrit.2019.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。